* GoodRx Holdings Inc GDRX.OQ GDRX.O is expected to show
a
rise in quarterly revenue when it reports results on August 8
for the period ending June 30 2024
* The Santa Monica California-based company is expected to
report
a 5.7% increase in revenue to $200.441 million from $189.68
million a year ago, according to the mean estimate from 16
analysts, based on LSEG data.The company's guidance on June 5
2024, for the period ended June 30, was for revenue of $190.000
million. (SAL is based on Total Revenue basis)
* LSEG's mean analyst estimate for GoodRx Holdings Inc is
for
earnings of 9 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 6
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for GoodRx
Holdings
Inc is $9.50, above its last closing price of $8.25.
The company's guidance on May 9 2024 for the period ended June
30 was for Earnings before Interest, Taxes, Depreciation and
Amortization of between USD190 million and USD68 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 0.07 0.08 0.08 Met 6.6
Jan. 1 2024 0.08 0.07 0.08 Beat 18.5
Sep. 30 2023 0.06 0.06 0.06 Met 3.8
Jun. 30 2023 0.06 0.06 0.07 Beat 15.8
Jan. 0.06 0.06 0.07 Beat 25.3
1 0001
Dec. 31 2022 0.05 0.05 0.07 Beat 52
Sep. 30 2022 0.04 0.04 0.07 Beat 72.6
Jan. 1 0001 0.04 0.04 0.06 Beat 54.4
This summary was machine generated August 6 at 18:34 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)